Huntsman Cancer Institute (HCI) at the University of Utah (U of U) is the only National Cancer Institute (NCI)-Designated Cancer Center in the State of Utah. It serves as the advanced cancer care center for the State, with a dedicated cancer specialty hospital, a statewide network of Cancer Learning Centers, training programs for cancer researchers and health care professionals, and a major commitment to cancer research -- with depth and breadth that spans basic laboratory research; clinical research, including early phase clinical trials; and prevention, control, and population-based research. HCI is also the only NCI-Designated Cancer Center in the five-state Intermountain West (Utah, Idaho, Montana, Nevada, and Wyoming). HCI fills a critical role in the national cancer program by serving this large geographical area and by conducting research that addresses aspects of the special cancer burden of rural and frontier populations and Native American groups that reside in the Intermountain West. Our Cancer Center has 136 members drawn from 27 academic departments in six colleges at the U of U. The members are supported by $54.8M in total extramural cancer research funding. HCI research is organized into four Research Programs that provide an environment of cancer focus and collaborative exchange: ? Nuclear Control of Cell Growth and Differentiation ? Cell Response and Regulation ? Experimental Therapeutics ? Cancer Control and Population Sciences HCI's Disease-Oriented Research Teams bring together members who share common disease-focused interests, providing an additional organizational structure to support transdisciplinary cancer research. HCI members published 1,419 cancer-focused, peer-reviewed publications from 2009-2013, of which 78% are collaborative, either within the Cancer Center or with external research partners. Support is requested for six HCI Shared Resources that provide access to specialized instrumentation, assays, services, research materials, and expert consultation and collaboration. These Shared Resources include the following: ? Utah Population Database ? Genetic Counseling ? Research Informatics ? Cancer Biostatistics ? Biorepository and Molecular Pathology ? High-Throughput Genomics and Bioinformatic Analysis In summary, HCI requests funds to support Years 26-30 of our Cancer Center Support Grant (CCSG), under the leadership of Mary Beckerle, Ph.D., HCI's Chief Executive Officer and Director. CCSG funding will support expenses associated with Cancer Center Shared Resources, Clinical Protocol and Data Management, Protocol Review and Monitoring, Program Leadership, Administration, and Developmental Funds.

Public Health Relevance

The genetic understanding of cancer has led to enhanced individual risk assessment, improved screening guidelines, and improved outcomes based on cancer prevention, early detection, and, in some cases, targeted therapy. Huntsman Cancer Institute is positioned to make exceptional contributions in this individualized oncology arena. The Cancer Center has a unique research resource to support genetic and population studies (the Utah Population Database), a compelling history of genetic discovery in oncology, and a strategic plan to accelerate translational advances from this platform. Through the work supported by our Cancer Center Support Grant, we aim to accelerate the progress of high-impact scientific discoveries across basic laboratory; clinical; and prevention, cancer control, and population-based research, as well as to disseminate these research findings to improve outcomes for individuals impacted by cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA042014-28S3
Application #
9378895
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-05-09
Project End
2020-04-30
Budget Start
2017-05-01
Budget End
2018-04-30
Support Year
28
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Utah
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Vahrenkamp, Jeffery M; Yang, Chieh-Hsiang; Rodriguez, Adriana C et al. (2018) Clinical and Genomic Crosstalk between Glucocorticoid Receptor and Estrogen Receptor ? In Endometrial Cancer. Cell Rep 22:2995-3005
Gupta, Sumati; Albertson, Daniel; Gaston, David et al. (2018) Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System. Clin Genitourin Cancer 16:e373-e382
Yazdimamaghani, Mostafa; Moos, Philip J; Ghandehari, Hamidreza (2018) Global gene expression analysis of macrophage response induced by nonporous and porous silica nanoparticles. Nanomedicine 14:533-545
Petersen, Jenna; Koptiuch, Cathryn; Wu, Yelena P et al. (2018) Patterns of family communication and preferred resources for sharing information among families with a Lynch syndrome diagnosis. Patient Educ Couns 101:2011-2017
Flack, Caralyn E; Parkinson, John S (2018) A zipped-helix cap potentiates HAMP domain control of chemoreceptor signaling. Proc Natl Acad Sci U S A 115:E3519-E3528
Al-Agha, Abdulmoein Eid; Ahmed, Ihab Abdulhamed; Nuebel, Esther et al. (2018) Primary Ovarian Insufficiency and Azoospermia in Carriers of a Homozygous PSMC3IP Stop Gain Mutation. J Clin Endocrinol Metab 103:555-563
Blackburn, Brenna E; Ganz, Patricia A; Rowe, Kerry et al. (2018) Reproductive and gynecological complication risks among thyroid cancer survivors. J Cancer Surviv 12:702-711
Wu, Yelena P; Aspinwall, Lisa G; Nagelhout, Elizabeth et al. (2018) Development of an Educational Program Integrating Concepts of Genetic Risk and Preventive Strategies for Children with a Family History of Melanoma. J Cancer Educ 33:774-781
Pishas, Kathleen I; Drenberg, Christina D; Taslim, Cenny et al. (2018) Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. Mol Cancer Ther 17:1902-1916
Spiker, William Ryan; Brodke, Darrel S; Goz, Vadim et al. (2018) Evidence of an Inherited Predisposition for Spinal Cord Tumors. Global Spine J 8:340-344

Showing the most recent 10 out of 1193 publications